×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Videos
Maps
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Did you mean:
arGENX
Argenx isn't sweating over Vyvgart competitors: exec
Fierce Pharma
As argenx continues to scoop up biologics market share with its antibody fragment Vyvgart in generalized myasthenia gravis (gMG),...
2 weeks ago
argenx announces results of Annual General Meeting of Shareholders
Yahoo Finance
May 7, 2024 – 5:30pm ET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving...
2 weeks ago
Argenx readies a blockbuster opportunity with drug for autoimmune disease
STAT
The company has developed the IgG-lowering antibody Vyvgart to treat patients with chronic inflammatory demyelinating polyneuropathy,...
2 months ago
Argenx to stop clinical development of efgartigimod for AAV
ANCA Vasculitis News
Argenx is not advancing its development plans for efgartigimod in AAV, after considering Phase 3 trial data in two other autoimmune...
1 week ago
argenx Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
million in first quarter global net product sales FDA review ongoing for CIDP sBLA with PDUFA target action date of June 21, 2024 On track...
2 weeks ago
Argenx Earnings: Maintaining Our Fair Value Estimates as Vyvgart Is Approaching CIDP Approval
Morningstar
We're maintaining our $466/EUR 425 fair value estimates for Argenx following first-quarter results that were in line with our expectations,...
2 weeks ago
Argenx gears up to launch Vyvgart in next potential indication
Fierce Pharma
Argenx on Tuesday gave a detailed glimpse at positive data from its late-stage ADHERE trial testing Vyvgart Hytrulo—the subcutaneous version of...
1 month ago
argenx to Present at BofA Securities 2024 Health Care Conference
Yahoo Finance
May 7, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of...
3 weeks ago
argenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024
GlobeNewswire
May 2, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of...
3 weeks ago
In another blow, Argenx antibody therapy fails in trial for skin blistering condition
STAT
Argenx said it was stopping the development of its antibody therapy in the autoimmune condition after the failed trial.
5 months ago